Galmed Pharmaceuticals (GLMD) Enterprise Value (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Enterprise Value of -$11.9 million for Q1 2026, up 2.55% year-over-year from -$11.6 million in Q1 2025, and down 7.9% quarter-over-quarter from -$11.0 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Enterprise Value (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Enterprise Value history runs 14 years deep, the most recent figure standing at -$11.9 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 2.55% year-over-year to -$11.9 million; the TTM figure through Mar 2026 stood at -$11.9 million (up 2.55% YoY), while the FY2025 annual figure was -$11.0 million, down 42.06% from the prior year.
- Enterprise Value for Q1 2026 stood at -$11.9 million, down from -$11.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$2.1 million in Q4 2024, with the low at -$28.7 million in Q1 2022.
- The 5-year median for Enterprise Value is -$12.0 million (2023), against an average of -$13.4 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 80.1% in 2024, then slumped 432.66% in 2025.
- Galmed Pharmaceuticals' Enterprise Value stood at -$13.8 million in 2022, then grew by 24.64% to -$10.4 million in 2023, then soared by 80.1% to -$2.1 million in 2024, then plunged by 432.66% to -$11.0 million in 2025, then slipped by 7.9% to -$11.9 million in 2026.
- Business Quant data shows GLMD's Enterprise Value at -$11.9 million in Q1 2026, -$11.0 million in Q4 2025, and -$13.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | -11.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.88 Mn |
| Dec 31, 2025 | -11.01 Mn |
| Sep 30, 2025 | -12.95 Mn |
| Jun 30, 2025 | -13.06 Mn |
| Mar 31, 2025 | -12.19 Mn |
| Dec 31, 2024 | -2.07 Mn |
| Sep 30, 2024 | -16.42 Mn |
| Jun 30, 2024 | -8.92 Mn |
| Mar 31, 2024 | -9.69 Mn |
| Dec 31, 2023 | -10.39 Mn |
| Sep 30, 2023 | -12.04 Mn |
| Jun 30, 2023 | -9.69 Mn |
| Mar 31, 2023 | -11.86 Mn |
| Dec 31, 2022 | -13.79 Mn |
| Sep 30, 2022 | -19.21 Mn |
| Jun 30, 2022 | -23.42 Mn |
| Mar 31, 2022 | -28.74 Mn |
| Dec 31, 2021 | -34.82 Mn |
| Sep 30, 2021 | -45.48 Mn |
| Jun 30, 2021 | -49.26 Mn |